Callan Family Office’s Ingevity NGVT Stock Holding History

Callan Family Office’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Sell	16,812 -448	-3%	-$30.6K	0.03%	510
2025 Q4	$1.02M	Buy	+17,260	New	+$937K	0.02%	542

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

SCM

Simcoe Capital Management New York $576M AUM 36.22% 1-Year Est. Return

Callan Family Office's NGVT Position: Q1 2026 in Review

Callan Family Office reduced its Ingevity (NGVT) stake by 2.6% in Q1 2026, selling an estimated $30.6K and leaving 16,812 shares worth $1.2M. The position accounts for 0.03% of the portfolio, ranked #510.

Callan Family Office first reported a position in NGVT in Q4 2025 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.

Callan Family Office held 16,812 shares of Ingevity worth $1.2M as of Q1 2026.
Callan Family Office sold 448 Ingevity shares in Q1 2026, an estimated $30.6K.
Ingevity made up 0.03% of Callan Family Office's portfolio in Q1 2026, its #510 holding.
Callan Family Office first reported a position in Ingevity in Q4 2025 and has held it in 2 quarters since.
307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.